New Two-Pronged cell therapy attacks stubborn blood cancer
NCT ID NCT06235229
Summary
This study is testing a new type of personalized cell therapy called GC012F for people with multiple myeloma that has come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them in a lab to better hunt cancer, and then infuse them back. The main goals are to see if the treatment is safe, what dose works best, and how well it controls the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
ACTIVE_NOT_RECRUITINGBeijing, 100024, China
-
Research Site
RECRUITINGBeijing, 102200, China
-
Research Site
RECRUITINGHangzhou, 310003, China
-
Research Site
RECRUITINGJinan, 250117, China
-
Research Site
RECRUITINGShanghai, 200003, China
-
Research Site
RECRUITINGShanghai, 201210, China
-
Research Site
RECRUITINGShenyang, 110134, China
-
Research Site
RECRUITINGWenzhou, 325000, China
-
Research Site
RECRUITINGWuhan, 430030, China
-
Research Site
ACTIVE_NOT_RECRUITINGXi'an, 710004, China
Conditions
Explore the condition pages connected to this study.